Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus Scientific Evidence and Practical Aspects

Use of Tirzepatide in adults with Type 2 Diabetes Mellitus: Scientific evidence and practical aspects

Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist , approved in the USA and in EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence.

A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial programme followed a nominal group technique, a qualitative research methodology designed as a semi structured group discussion, to reach a consensus on the selection of a set of practical aspects.

The scientific evidence for tirzepatide has been reviewed with respect to a number of patients’ clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized.

The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing T2DM management.

Download PDF Outside URL
Skip to content